L., Nauck, M
(See Figure 2 for a timeline of key activities associated with the GLP-1 coverage demonstrations.) Medicare coverage of GLP-1s for obesity begins in July 2026 through the Medicare GLP-1 Bridge and will be extended through the end of 2027 CMS will provide Part D beneficiaries with coverage of select GLP-1s for obesity from July 1, 2026 to December 31, 2027 (originally December 31, 2026) through the Medicare GLP-1 Bridge, which is a short-term demonstration established using Section 402 demonstration authority
This can happen even if you have never had heart failure or heart problems before
Recently, a comprehensive cohort study utilizing data from the Korean National Health Insurance Service from 2004 to 2021 indicated no significant correlation between GLP-1 RAs and the incidence of new-onset malignancies, with a median follow-up of 8 years [109]
Visceral versus subcutaneous fat While the trial did not break down visceral and subcutaneous fat reduction separately using imaging for all participants, the liver fat data serves as a strong proxy
GLP-1 medications, like Ozempic and Wegovy, have shown promising results for weight loss and metabolic health
